EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FOXR2 activation is not exclusive of CNS neuroblastoma

Alexa N Siskar, Emily Hanzlik, Maria F Cardenas, Mohammad K Eldomery, Soniya Pinto, Christopher L Tinkle, Qunyu Zhang, Xiaoyu Li, Tong Lin, Sandeep K Dhanda, Gerald Reis, Daphne Li und 8 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Alexa N Siskar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Forkhead Transcription Factors, Central Nervous System Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Jude Comprehensive Cancer Center, American Lebanese Syrian Associated Charities, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

FOXR2 activation is regarded as pathognomonic for CNS neuroblastoma (NB). However, a comprehensive understanding of the landscape for CNS tumors exhibiting FOXR2 activation is lacking.

Methods

Histopathologic, molecular, imaging, and clinical data of 42 CNS tumors with FOXR2 overexpression identified through screening institutional datasets and published institutional cases were analyzed.

Results

Among the 42 tumors, 21 (50.0%) were high-grade gliomas (HGGs), and 18 (42.9%) were embryonal tumors. The HGGs included ten H3 K27M-mutant diffuse midline gliomas (DMGs) and eight radiation-associated tumors. The embryonal tumors included 11 CNS NBs and six pineoblastomas (PBs). FOXR2 expression was similar between CNS NB and other tumor types (P = 0.82). HGGs with FOXR2 overexpression, unlike NBs and PBs, displayed diverse concomitant genetic alterations. The most common mechanisms of FOXR2 activation involved structural alterations causing promoter donation and enhancer hijacking from active genes essential for brain development, followed by alternative promoter activation or truncated LINE-1 retrotransposition. The preferential activation mechanism varied by tumor type. All but two aberrant FOXR2 transcripts incorporated non-canonical, non-coding exons. Gene set enrichment analysis demonstrated shared downstream effects of FOXR2 activation at the epigenome and transcriptome levels across tumor types. DMGs and PBs with FOXR2 overexpression were aggressive, with 0% 2-year overall survival, whereas CNS NBs responded well to combined chemotherapy and radiation.

Conclusions

CNS tumors with FOXR2 overexpression manifest significant histological, molecular, imaging, and clinical diversity. While HGGs and PBs with FOXR2 overexpression demonstrated inferior prognosis, CNS NBs showed favorable outcomes. Integrating histologic and molecular diagnostic approaches is imperative for accurate prognostication and optimal therapeutic decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaForkhead Transcription FactorsCentral Nervous System NeoplasmsBiomarkers, TumorGliomaHumansFemaleMalePrognosisChildChild, PreschoolInfantGene Expression Regulation, NeoplasticAdolescentAdultFollow-Up Studies

Stichwörter der Autor:innen

CNS tumors with FOXR2 overexpressionLINE-1 retrotranspositionalternative promoterpatient outcomespromoter donation and enhancer hijacking

Substanzen

Forkhead Transcription FactorsFOXR2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Radiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.

ORCID-Profile: Arzu Onar-Thomas, Jason Chiang

Förderung

  • St. Jude Comprehensive Cancer Center
  • American Lebanese Syrian Associated Charities
  • NIH
  • V Foundation
  • NCI NIH HHS
  • Memorial Sloan Kettering Cancer Center
  • NCI Program Project
  • NCI

Zitieren

APA

Siskar, A. N., Hanzlik, E., Cardenas, M. F., Eldomery, M. K., Pinto, S., Tinkle, C. L., Zhang, Q., Li, X., Lin, T., Dhanda, S. K., Reis, G., Li, D., Raghavan, R., Vortmeyer, A., Karajannis, M. A., Robinson, G. W., Onar-Thomas, A., Blackburn, P. R., Wheeler, D. A., & Chiang, J. (2025). FOXR2 activation is not exclusive of CNS neuroblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf076

Vancouver

Siskar AN, Hanzlik E, Cardenas MF, Eldomery MK, Pinto S, Tinkle CL, et al. FOXR2 activation is not exclusive of CNS neuroblastoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf076

BibTeX
@article{Siskar2025,
  author = {Siskar, Alexa N and Hanzlik, Emily and Cardenas, Maria F and Eldomery, Mohammad K and Pinto, Soniya and Tinkle, Christopher L and Zhang, Qunyu and Li, Xiaoyu and Lin, Tong and Dhanda, Sandeep K and Reis, Gerald and Li, Daphne and Raghavan, Ravi and Vortmeyer, Alexander and Karajannis, Matthias A and Robinson, Giles W and Onar-Thomas, Arzu and Blackburn, Patrick R and Wheeler, David A and Chiang, Jason},
  title = {FOXR2 activation is not exclusive of CNS neuroblastoma},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf076}
}
Kostenlos starten →